Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

NCT00725842 · clinicaltrials.gov ↗

TERMINATED

Status

97

Enrollment

INDUSTRY

Sponsor class

Stopped Low enrollment

Conditions

Hepatitis C
Hepatitis C, Chronic

Interventions

BIOLOGICAL: Peg-IFN alfa-2b
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC